1-3 of 3
Edward Faber, DO
Close
Sort by
Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 863.
https://doi.org/10.1182/blood-2019-122497
Published: 2019
Journal Articles

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, DO, MS, William Bensinger, MD, John M Burke, Mohit Narang, MD, Don Stevens, MD, Sriya W. Gunawardena, MD, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Robert M Rifkin, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 152.
https://doi.org/10.1182/blood-2018-152
Published: 2018
Journal Articles

Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Jeffrey A Zonder, MD, Saad Usmani, Emma C. Scott, MD, Craig C. Hofmeister, MD, Nikoletta Lendvai, MDPhD, Jesus G. Berdeja, MD, Larry D. Anderson, Jr., MD PhD, Parameswaran Hari, MBBS, MD MRCP, Seema Singhal, MD, Gregory Orloff, MD, Michael Craig, MD, Jason Valent, MD, Wes Lee, Lowell Hart, J Hrom, Stephano Tarantolo, Edward Faber, DO, Gary J Schiller, MD, Jennifer Schreiber, BS, Colleen Oliver, MSc, Selena A Rush, BS, Brian Tunquist, Mieke Ptaszynski, Noopur S. Raje, MD
Journal: Blood
Blood (2015) 126 (23): 728.
https://doi.org/10.1182/blood.V126.23.728.728
Published: 2015